Citations

Clear

862 citation(s) found for "Habermann, EB".

Concordance Between Registry and Administrative Data in the Determination of Comorbidity
Etzioni, David A. , Lessow, Cynthia, Bordeianou, Liliana , Kunitake, Hiroko , Deery, Sarah E. , Papageorge, Christina M. , Fuhrman, George M. , Seiler, Rachel L., Ogilvie, James W. , Habermann, Elizabeth B. , Money, Samuel R., Habermann, Elizabeth , Carchman, Evie H. , Chang, Yu‐Hui

Mayo Clinic

Annals of Surgery | March 3, 2019 | Volume: 272 | Issue: 6 | Pages: 1006-1011

10.1097/sla.0000000000003247 | PMID 30817356 Get It

Objective: To characterize agreement between administrative and registry data in the determination of patient-level comorbidities. Background: Previous research finds poor agreement between these 2 types of data in the determination of outcomes. We hypothesized that concordance between administrative and registry data would also be poor. Methods: A cohort of inpatient operations (length of stay 1 day or greater) was obtained from a consortium of 8 hospitals. Within each hospital, National Surgical Quality Improvement Program (NSQIP) data were merged with intra-institutional inpatient administrative data. Twelve different comorbidities (diabetes, hypertension, congestive heart failure, hemodialysis-dependence, cancer diagnosis, chronic obstructive pulmonary disease, ascites, sepsis, smoking, steroid, congestive heart failure, acute renal failure, and dyspnea) were analyzed in terms of agreement between administrative and NSQIP data. Results: Forty-one thousand four hundred thirty-two inpatient surgical hospitalizations were analyzed in this study. Concordance (Cohen Kappa value) between the 2 data sources varied from 0.79 (diabetes) to 0.02 (dyspnea). Hospital variation in concordance (intersite variation) was quantified using a test of homogeneity. This test found significant intersite variation at a level of P < 0.001 for each of the comorbidities except for dialysis (P = 0.07) and acute renal failure (P = 0.19). These findings imply significant differences between hospitals in their generation of comorbidity data. Conclusion: This study finds significant differences in how administrative versus registry data assess patient-level comorbidity. These differences are of concern to patients, payers, and providers, each of which had a stake in the integrity of these data. Standardized definitions of comorbidity and periodic audits are necessary to ensure data accuracy and minimize bias.
Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
Wang, Sophia , Sarangi, Vivekananda , Link, Brian K. , Inwards, David J. , Witzig, Thomas E. , Rothman, Nathaniel , Asmann, Yan W. , Witzig, T.E. , Asmann, Yan, Cerhan, James R , Link, Brian K , Wang, Sophia S , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Cozen, Wendy , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | February 28, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25451 | PMID 30815899 Get It

Does Metabolic Syndrome Increase the Risk of Postoperative Complications in Patients Undergoing Colorectal Cancer Surgery?
Shariq, Omair A. , Hanson, Kristine T. , McKenna, Nicholas P. , Dozois, Eric J. , Mathis, Kellie L. , Habermann, Elizabeth B. , Kelley, Scott R. , Habermann, Elizabeth , McKenna, Nicholas P , Lightner, Amy L. , Hanson, Kristine

Mayo Clinic

Diseases of the Colon & Rectum | February 2, 2019 | Volume: 62 | Issue: 7 | Pages: 849-858

10.1097/dcr.0000000000001334 | PMID 31188186 Get It

BACKGROUND: Metabolic syndrome is associated with poorer postoperative outcomes after various abdominal operations. However, the impact of metabolic syndrome on outcomes after colorectal cancer surgery remains poorly described. OBJECTIVE: The purpose of this study was to determine the association between metabolic syndrome and short-term postoperative outcomes in patients undergoing elective colorectal cancer surgery. DESIGN: This was a retrospective cohort study. SETTINGS: This study used a national multicenter database. PATIENTS: Adult patients who underwent elective colectomy for colorectal cancer from 2010 to 2016 were identified in the American College of Surgeons National Surgical Quality Improvement Program database. MAIN OUTCOME MEASURES: Thirty-day postoperative mortality and morbidity, unplanned reoperation, unplanned readmission, operative time, and length of stay were measured. RESULTS: A total of 91,566 patients were analyzed; 7603 (8.3%) had metabolic syndrome. On unadjusted analysis, metabolic syndrome was associated with an increased risk of 30-day overall morbidity, pulmonary complications, renal complications, septic complications, cardiac complications, wound complications, blood transfusion, longer length of stay, and unplanned readmissions. On multivariable analysis, metabolic syndrome remained significantly associated with renal complications (OR = 1.44 (95% CI, 1.29–1.60)), superficial surgical site infection (OR = 1.46 (95% CI, 1.32–1.60)), deep surgical site infection (OR = 1.40 (95% CI, 1.15–1.70)), wound dehiscence (OR = 1.47 (95% CI, 1.20–1.80)), and unplanned readmissions (HR = 1.24 (95% CI, 1.15–1.34)). The risks of overall morbidity, cardiac and septic complications, and prolonged length of stay for laparoscopic procedures were significantly associated with diabetes mellitus rather than metabolic syndrome as a composite entity. LIMITATIONS: This study was limited by its retrospective design and inability to analyze outcomes beyond 30 days. CONCLUSIONS: Patients with metabolic syndrome undergoing elective surgery for colorectal cancer have an increased risk of 30-day postoperative renal complications, wound complications, and unplanned hospital readmissions. A multidisciplinary approach involving lifestyle modifications and pharmacologic interventions to improve the components of metabolic syndrome should be implemented preoperatively for these patients. See Video Abstract at http://links.lww.com/DCR/A909.
An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.
Asmann, Yan W. , Necela, Brian M. , Chen, Xianfeng , Kocher, Jean‐Pierre , Feldman, Andew L., Novak, Anne J. , Perez, Edith A. , Thompson, E. Aubrey , Wang, Chen , Maurer, Matthew J. , Habermann, Thomas M. , Slager, Susan L. , Doǧan, Ahmet , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e22171-e22171

10.1200/jco.2014.32.15_suppl.e22171 Get It

Utility of restaging bone marrow biopsy (BMB) in PET-negative patients with diffuse large B-cell lymphoma (DLBCL) with bone marrow involvement.
Jackson, Amie E., Smeltzer, Jacob P., Jones, Jason M. , Burnette, Brian L., Ristow, Kay M., Wiseman, Gregory A., Macon, William R. , Nowakowski, Grzegorz S. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8541-8541

10.1200/jco.2014.32.15_suppl.8541 Get It

Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study.
Nowakowski, Grzegorz S. , LaPlant, Betsy, Macon, William R. , Reeder, Craig B. , Foran, James M. , Nelson, Garth D. , Thompson, Carrie A. , Rivera, Candido E., Inwards, David J. , Micallef, Ivana N. , Johnston, Patrick B. , Porrata, Luis F. , Ansell, Stephen M. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8520-8520

10.1200/jco.2014.32.15_suppl.8520 Get It

Cardiovascular screening in long-term Hodgkin lymphoma survivors.
Thompson, Carrie A. , Ristow, Kay M., Herrmann, Joerg , Griffin, Benjamin R. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e20592-e20592

10.1200/jco.2014.32.15_suppl.e20592 Get It

Older patients and risk of developing and dying from bleomycin-induced lung toxicity.
Marri, Preethi, Ristow, Kay M., Rodriguez, Vilmarie , Ansell, Stephen M. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8584-8584

10.1200/jco.2014.32.15_suppl.8584 Get It

Geographical Differences in Intracranial Meningioma Management: Examining 65,973 Patients across the United States
Anzalone, C. Lane , Glasgow, Amy E. , Habermann, Elizabeth B. , Grossard, Brandon R., Carlson, Matthew L. , Glasgow, Amy E. , Anzalone, Charles Lane, Glasgow, Amy, Habermann, Elizabeth , Gompel, Jamie J. Van , Glasgow, Amy E

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | December 26, 2018 | Volume: 80 | Issue: 06 | Pages: 547-554

10.1055/s-0038-1676376 | PMID 31754594 Get It

Background Age, tumor size and location, overall health, and patient preference are primary considerations driving treatment decision-making for intracranial meningiomas. However, even for the same individual patient, treatment recommendations may vary between centers and providers. Objective To study associations between geography, disease presentation, and management of intracranial meningioma in the United States. Methods The population-based Surveillance, Epidemiology, and End Results(SEER) data were queried between 2004 and 2014 for cases of intracranial meningioma. Results A total of 65,808 patients with intracranial meningioma were identified. Univariate analyses demonstrated strong associations between geographic location, age, and size of tumor at presentation. The mean age for all registries was 64.2 years, with a range from 62.0 (Utah registry) to 66.6 (Detroit registry). The greatest proportion of small tumors (<1 cm) were identified in the Utah registry (13.9% of tumors), while the greatest proportion of large tumors (> 4cm) were noted in the Hawaii registry (30.7% of tumors). Multivariable analysis demonstrated that the impact of geography on treatment selection was just as important as other established variables. For example, the distribution in tumor size between New Mexico and Greater California registries is nearly identical; however, the odds ratio for surgery was 1.5 times greater for the New Mexico population. Conclusion These data suggest that disease presentation and treatment are significantly influenced by regional referral patterns, provider or institutional treatment preferences, and regional availability of subspecialty expertise. Understanding such biases is important for patients, referring physicians, and treatment providers in an effort to provide balanced counseling and treatment.
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
Hill, Brian T. , Winter, Allison , Becnel, Melody , Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Fakhri, Bita , Reddy, Prathima, Smith, Stephen D. , Mukhija, Dhruvika , Jagadeesh, Deepa , Desai, Amrita, Alderuccio, Juan Pablo , Lossos, Izidore S. , Mehra, Pooja , Portell, Craig A. , Goldman, Max L. , Calzada, Oscar , Cohen, Jonathon B. , Hussain, Mohammad Junaid, Tiutan, Timothy , Martin, Peter , Kodali, Abhigna, Evens, Andrew M. , Becnel, Melody R , Cerhan, James R , Link, Brian K , Maurer, Matthew , Calzada, Oscar , Martin, Peter , Evens, Andrew M , Hill, Brian , Fakhri, Bita , Portell, Craig A , Nastoupil, Loretta J. , Habermann, Thomas M. , Ghosh, Nilanjan , Caimi, Paolo F. , Kahl, Brad S.

Mayo Clinic

British Journal of Haematology | December 21, 2018 | Volume: 184 | Issue: 4 | Pages: 524-535

10.1111/bjh.15720 | PMID 30575016 Get It

SummaryBendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R‐CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.